Patents by Inventor Gino Luigi Vairo
Gino Luigi Vairo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210292424Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: March 18, 2021Publication date: September 23, 2021Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20200277389Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: September 24, 2019Publication date: September 3, 2020Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20200207861Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: July 19, 2019Publication date: July 2, 2020Applicants: CSL Limited, University Health NetworkInventors: John Edgar DICK, Liqing Jin, Gino Luigi VAIRO, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20180079818Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: May 5, 2017Publication date: March 22, 2018Applicants: CSL Limited, University Health NetworkInventors: John Edgar Dick, Liqing JIN, Gino Luigi VAIRO, David Paul GEARING, Samantha Jane BUSFIELD
-
Publication number: 20170362328Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: August 30, 2017Publication date: December 21, 2017Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Patent number: 9758585Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: GrantFiled: February 9, 2015Date of Patent: September 12, 2017Assignee: CSL LimitedInventors: Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield, Con Panousis
-
Publication number: 20170029515Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: August 10, 2016Publication date: February 2, 2017Applicants: CSL Limited, University Health NetworkInventors: John Edgar Dick, Liqing JIN, Gino Luigi VAIRO, David Paul GEARING, Samantha Jane BUSFIELD
-
Publication number: 20160304616Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Applicant: CSL LIMITEDInventors: Devendra Keshaorao Hiwase, Timothy Peter Hughes, Angel Francisco Lopez, Gino Luigi Vairo
-
Publication number: 20150152185Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: November 25, 2014Publication date: June 4, 2015Applicants: CSL LIMITED, UNIVERSITY HEALTH NETWORKInventors: JOHN EDGAR DICK, LIQING JIN, GINO LUIGI VAIRO, DAVID PAUL GEARING, SAMANTHA JANE BUSFIELD
-
Publication number: 20150147322Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: ApplicationFiled: February 9, 2015Publication date: May 28, 2015Inventors: Gino Luigi VAIRO, Andrew NASH, Eugene MARASKOVSKY, Nick WILSON, Samantha BUSFIELD, Con PANOUSIS
-
Publication number: 20150093355Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 17, 2014Publication date: April 2, 2015Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20150017180Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.Type: ApplicationFiled: May 12, 2014Publication date: January 15, 2015Applicant: CSL LimitedInventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
-
Publication number: 20140178364Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: ApplicationFiled: August 14, 2013Publication date: June 26, 2014Applicant: CSL LimitedInventors: Gino Luigi VAIRO, Andrew NASH, Eugene MARASKOVSKY, Nick WILSON, Samantha BUSFIELD
-
Patent number: 8535669Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: GrantFiled: February 17, 2011Date of Patent: September 17, 2013Assignee: CSL LimitedInventors: Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield
-
Publication number: 20130230510Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: December 4, 2012Publication date: September 5, 2013Applicants: University Health Network, CSL LimitedInventors: John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20130084282Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: ApplicationFiled: February 17, 2011Publication date: April 4, 2013Applicant: CSL LimitedInventors: Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield
-
Publication number: 20120244116Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: October 1, 2010Publication date: September 27, 2012Applicant: CSL LIMITEDInventors: Devendra Keshaorao Hiwase, Timothy Peter Hughes, Angel Francisco Lopez, Gino Luigi Vairo
-
Publication number: 20110052574Abstract: A method for inhibition of leukemic stem cells expressing IL-3R?; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: December 4, 2008Publication date: March 3, 2011Inventors: John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20100209341Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.Type: ApplicationFiled: February 17, 2010Publication date: August 19, 2010Inventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
-
Patent number: 6710075Abstract: The present invention provides compounds having a cyclopentabenzofuran core and the use of such compounds in therapy as well as compositions comprising said compounds.Type: GrantFiled: November 8, 2002Date of Patent: March 23, 2004Assignee: The Government of the State of Sarawak, MalaysiaInventors: Barbara Martha Meurer-Grimes, Jin Yu, Gino Luigi Vairo